The Impact of Intravitreal Injection of Anti-vascular Endothelial Growth Factor Faricimab on Renal Function in Patients With Diabetes Mellitus

What this Trial Is About

Researchers are studying the effects of the anti-vascular endothelial growth factor (anti-VEGF) drug Faricimab on kidney function in diabetic patients. This study focuses on patients with diabetic macular edema or neovascular age-related macular degeneration who require intravitreal injections. Since previous anti-VEGF drugs may affect kidney function, this trial aims to understand how Faricimab, which targets both VEGF-A and Ang-2, influences renal health in patients who may already have kidney issues due to diabetes. A total of 60 diabetic patients needing anti-VEGF treatment will be randomly assigned to two groups: one receiving intravitreal injections of Faricimab and the other receiving Aflibercept 2 mg. Both drugs are given directly into the eye. Before starting treatment, participants will have lab tests to assess blood sugar control and kidney function, including HbA1c, estimated glomerular filtration rate (eGFR), plasma creatinine, and urine albumin to creatinine ratio (ACR). Eye exams will also be done to check vision, eye pressure, and macular thickness using optical coherence tomography. Participants will be followed for one year, with assessments at the start, six months, and twelve months after treatment begins. Researchers will monitor kidney function through eGFR and ACR measurements and evaluate eye health and vision improvements. The study includes regular eye exams and laboratory tests during each visit. Statistical analysis will be performed at the end to compare the effects of the two treatments on kidney function and eye health in diabetic patients.

Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients